The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced its participation as a sponsor of thefirst-ever Phelan-McDermid syndrome (PMS) burden of illness study. 

The venture capital company, Ysios Capital, a member of Catalonia.health, announced that its investee VarmX has signed a strategic development agreement with global biopharmaceutical company CSL (ASX:CSL), which includes an exclusive option to purchase the company.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that it has been selected as a finalist in the 2025 European Lifestars  Awards in the category Post-IPO Raise of the Year for the European Mediterranean region.

The venture capital company Asabys Partners, a member of Catalonia.health, leads €10 million extension of its oversubscribed €35 million Series C financing round through its Sabadell Asabys II fund

The biotechnology company CONNECTA Therapeutics, a member of Catalonia.health, has announced the launch of studies for the paediatric development program of CTH120, an investigational FXS treatment, following positive results from the Phase I trial.

The biotech company Integra Therapeutics, a member of Catalonia.health, has announced it has closed a €10.7 million pre–Series A round of investment to advance the development of its FiCAT genetic editing platform and the preclinical validation of CAR-T therapies.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND, to initiate a Phase Ib trial of iadademstat in sickle cell disease (SCD). This will be the first clinical trial investigating iadademstat in a non-malignant hematological indication.

The pharmaceutical HIPRA, a member of Catalonia.health, is leading the European project SPEEDCELL, with the goal of transforming the development of vaccines and other biotechnological products to address future health crises.

The Eurecat technology centre, in collaboration with Doole Health, both members of Catalonia.health, have developed an advanced telerehabilitation platform called Rehabilify, which enables patients to continue their treatment from home, maintain contact with medical teams and ensure personalised, effective and continuous monitoring.

The clinical-stage biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced its financial results for the first half of 2025 and shared updates on its clinical and corporate progress.

The plastic packaging and container manufacturing company Industrias Plásticas Triana, a member of Catalonia.health, has obtained ISCC Plus and UNE-EN 15343certifications, two important milestones in its sustainability strategy. 

Personalised medicine company Inbiomotion, a member of Catalonia.health, announces that MAF Test® will be available at the Hospital del Mar in Barcelona, also a member of Catalonia.health, the Clínic Barcelona Comprehensive Cancer Center, the HM Hospitals centres in the Community of Madrid, and the International Breast Cancer Center/Pangaea Oncology (Barcelona).

The biotechnology company Microomics, a member of Catalonia.health, has announced a restructure of its executive team in order to embark on a new growth phase.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that they have received the “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804and IL272092

The deeptech company DevsHealth, a member of Catalonia.health, and the Foundation for the Research of Neglected Diseases (FNDR), based in India, announce the identification of DHFLV_003B, the first antiviral compound against dengue conceived entirely with AI thanks to the DevsHealth computational platform.

The financial services company Inveready, a member of Catalonia.health, announces the successful closure of its life sciences fund Inveready Innvierte Biotech II.

The pharmaceutical company Medichem, a member of Catalonia.health, have earned B Corp certification, awarded by B Lab. With this recognition, Medichem joins a global movement of companies that meet high standards of social and environmental performance, transparency, and corporate accountability.

Biotechnology company Admit Therapeutics, a member of Catalonia.health, announced its relocation to new, expanded laboratory and office spaces within Almirall’s Innovation Hub "The Hive" at the existing R&D center in Sant Feliu de Llobregat, also a member of Catalonia.health.

The startup The Smart Lollipop, a member of Catalonia.health, has opened an investment round Series A of 2.5 million euros in order to launch its smart candy that diagnoses diseases with saliva analysis.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and a European leader in epigenetics announced that it has submitted the clinical trial  protocol for its Phase III PORTICO-2 trial to the U.S. FDA to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD).